Q2 2025 Holdings
Filed 2025-08-13 | 91 holdings | $732.2M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Verona Pharma PLC(VRNA) | SPONSORED ADS | 925050106 | $57.7M | 610,000 | 7.9% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $47.8M | 475,000 | 6.5% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $34.4M | 1,100,000 | 4.7% |
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $32.6M | 495,000 | 4.5% |
| Blueprint Medicines Corp(2L9) | COM | 09627Y109 | $32.0M | 250,000 | 4.4% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $31.7M | 415,000 | 4.3% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $30.0M | 691,899 | 4.1% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $28.6M | 1,000,000 | 3.9% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $24.3M | 440,000 | 3.3% |
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $24.2M | 80,000 | 3.3% |
| Teva Pharmaceutical Inds LTD(TEVA) | SPONSORED ADS | 881624209 | $23.5M | 1,400,000 | 3.2% |
| Exelixis Inc(EXEL)Put | COM | 30161Q104 | $19.8M | 450,000 | 2.7% |
| Lexeo Therapeutics Inc(LXEO) | COM | 52886X107 | $14.4M | 3,589,355 | 2.0% |
| Travere Therapeutics Inc(TVTX) | COM | 89422G107 | $14.4M | 970,000 | 2.0% |
| Establishment Labs Hldgs Inc(ESTA) | COM | G31249108 | $14.3M | 334,863 | 2.0% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $13.9M | 2,534,058 | 1.9% |
| Wave Life Sciences LTD(WVE) | SHS | Y95308105 | $13.0M | 2,000,308 | 1.8% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $12.8M | 545,000 | 1.8% |
| Mineralys Therapeutics Inc(MLYS) | COM | 603170101 | $12.2M | 900,000 | 1.7% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $11.8M | 900,162 | 1.6% |
| Karyopharm Therapeutics Inc | NOTE 3.000%10/1 | 48576UAA4 | $11.6M | $15,250,000 | 1.6% |
| Amgen Inc(AMGN)Call | COM | 031162100 | $11.2M | 40,000 | 1.5% |
| Nurix Therapeutics Inc(NRIX) | COM | 67080M103 | $11.0M | 967,620 | 1.5% |
| Rezolute Inc(RZLT) | COM NEW | 76200L309 | $9.8M | 2,200,000 | 1.3% |
| Crispr Therapeutics AG(CRSP)Call | COM | H17182108 | $9.7M | 200,000 | 1.3% |
| Ventyx Biosciences Inc(VTYX) | COM | 92332V107 | $9.7M | 4,536,182 | 1.3% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $9.1M | 606,678 | 1.2% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $8.0M | 400,000 | 1.1% |
| Proqr Thrapeutics N V | SHS EURO | N71542109 | $7.1M | 3,499,512 | 1.0% |
| Akebia Therapeutics Inc(AKBA) | COM | 00972D105 | $7.1M | 1,950,000 | 1.0% |
| Omeros Corp | NOTE 9.500% 6/1 | 682143AK8 | $7.1M | $9,025,000 | 1.0% |
| Inozyme Pharma Inc | COM | 45790W108 | $7.0M | 1,749,359 | 1.0% |
| Autolus Therapeutics PLC(AUTL) | SPON ADS | 05280R100 | $6.9M | 3,045,000 | 0.9% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $6.8M | 603,479 | 0.9% |
| Travere Therapeutics Inc | NOTE 2.250% 3/0 | 89422GAA5 | $6.7M | $7,000,000 | 0.9% |
| Exelixis Inc(EXEL)Call | COM | 30161Q104 | $6.6M | 150,000 | 0.9% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $6.5M | 150,000 | 0.9% |
| Viridian Therapeutics Inc(VRDN) | COM | 92790C104 | $5.5M | 390,000 | 0.7% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $5.2M | 50,000 | 0.7% |
| Erasca Inc(ERAS) | COM | 29479A108 | $5.2M | 4,085,787 | 0.7% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $5.0M | 275,000 | 0.7% |
| Crescent Biopharma Inc.(CBIO) | COM | G2545C104 | $4.5M | 280,031 | 0.6% |
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $4.5M | 400,000 | 0.6% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $4.4M | 152,252 | 0.6% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $4.1M | 125,000 | 0.6% |
| Perceptive Cap Solutions COR | CL A ORD SHS | G70077105 | $3.7M | 350,000 | 0.5% |
| Merus N V | COM | N5749R100 | $3.7M | 70,000 | 0.5% |
| Perspective Therapeutics Inc(CATX) | COM NEW | 46489V302 | $3.6M | 1,050,000 | 0.5% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $3.0M | 607,872 | 0.4% |
| Oaktree Acquisition Corp III | UNIT 10/04/2029 | G6717R120 | $2.7M | 250,000 | 0.4% |